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Abstract  
Background:Thyroid dysfunction is a known adverse effect of some tyrosine kinase inhibitors like sunitiniband 
sorafenib while imatinib hasbeen shown to induce hypothyroidism and increased requirement of levothyroxine in 
thyrectomizedpatients. Very few retrospective studies are available for CML patients treated with imatinib,which 
havedemonstrated conflicting effects on thyroid function. 
Experimental design: We have prospectively studied thyroid function at baseline and at 6 months of imatinib treatment 
in 30 newly diagnosed BCR-ABL positive CML patients.  
Results:Two (6.7%) patients had subclinical hypothyroidism at diagnosis with the prevalence not being different from 
general population. Though the TSH levels increased significantly from baseline (3.80±2.00 mIU/L vs. 3.14±1.65 
mIU/L, p =0.016) after6 months of treatment, 90% of the patients remained euthyroid. Only 3 patients had subclinical 
hypothyroidism.  
Conclusion:Imatinib did not have any significant impact on thyroid function in CML patients but may possibly alter the 
peripheral metabolism of thyroid hormones.  
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Introduction 
CML  
Chronic myelogenous leukemia (CML) is a 
myeoloproliferative disorder characterized by anaemia, 
extreme blood granulocytosis, granulocytic immaturity, 
basophilia, often thrombocytosis, and 
splenomegaly[1].The hematopoietic cells contain the 
fusion gene BCR-ABL, which encodes a constitutively 
active tyrosine kinase responsible for the initiation and 
maintenance of the chronic phase of CML[2,3].The natural 
history of the chronic phase of the disease is to 
undergo clonal evolution into an accelerated phase 
and/or a rapidly progressive phase (blast crisis) 
resembling acute leukemia in a median time of four 
years, which is refractory to therapy[4].Imatinib 
mesylate is a smallmolecular analogue ofATPthat 
functions through competitive inhibition at the ATPbinding 
site of the ABL kinase in the inactive conformation, which 
leads to inhibition of tyrosine phosphorylation of proteins 
involved in BCR-ABL signal transduction[1,5].Imatinib 
induces apoptosis in cells expressing BCR-ABL[1].The goal 
of imatinib therapy is to decrease the cells bearing the t(9;22) 
translocation (leukemic cells) to the lowest levels possible 
(BCR-ABL/ABL expression ratio <0.05% by 18 months of 
therapy), under which conditions normal (polyclonal) 
haematopoiesis is restored[1]. 
Besides BCR–ABLimatinib mesylateis known to potently 
inhibit theplatelet derived growth factor receptor-α 
(PDGFR-α), PDGFR-β, c-Fms, Arg and c-kit (stem cell 
factor receptor) tyrosine kinases[6].Action on these tyrosine 
kinases may be responsible for many of the documented side 
effects of imatinib and effects on multiple endocrine 
hormones as well[6].The leukemic stem cells (quiescent 
Ph-chromosome–positive cells, CD34+Lin–) are insensitive 
to imatinib in vitro, thus at present it is advisable to maintain 
treatment indefinitely until the criteria for cessation, if any, 
can be established in clinical trials[1,7].Effects of imatinib on 
multiple endocrine hormones are being recognized and may 
affect quality of life in the CML patientsand cause 
compliance issues. 
Tyrosine kinase inhibitors and thyroid 
dysfunction 
Sunitinib and sorafenib are multitargeted tyrosine kinase 
inhibitors that have been demonstrated to induce 
hypothyroidism by multiple studies[8].Retrospective studies 
indicate that sunitinib can induce hypothyroidism in 53-85% 
of patients, and in prospective studies this complication has 
been reported in 36-71% of patients[8-10]. Sorafenib has 
been reported to be responsible for hypothyroidism in 18% 
of patients with metastatic renal-cell carcinoma[11].Due to 
similar mechanisms of action, it is possible that imatinib is 
also associated with thyroid dysfunction[8]. 
Kim et al. detected thyroid abnormalities in 25%, 55%, and 
70% of Philadelphia chromosome positive CML patients 
under treatment with imatinib, nilotinib, and 
dasatinibrespectively[12].Dora et al., reported normal TSH 
in 63 (92.6%)out of 68 CML patients on imatinib therapy,but 
elevated TSH (5.08-12.55 mU/L)in 5 (7.4%) patients[13]. 
Groot et al. described increased symptomatic requirement of 
levothyroxine and elevated TSH levels in previously 
thyroidectomizedpatients receiving imatinib for 
gastrointestinal stromal tumor ormedullary thyroid 
carcinoma[14,15]. 
Although generally well tolerated, common side-effects of 
imatinib are fatigue and periorbital and peripheral 
oedema[1,4].Symptoms of hypothyroidism are almost 
undistinguishable from these side-effects[14].With the above 
background of conflicting reports and scarcity of prospective 
studies on the effect of imatinib on thyroid function in 
CMLpatients, we planned to study the thyroid function in 
CML patients on treatment with imatinib mesylate in 
comparison to the baseline levels.  
Material & methods 
Patient selection and study design 
The present study was a prospective, observational and 
non-randomized study conducted on 30 newly 
diagnosed patients of CML in chronic phase. Patients 
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were enrolled from the Haematology Clinic at Pt. BD 
Sharma Post graduate Institute of Medical Sciences, 
Rohtak, Haryana after obtaining informed consent. 
The studywas conducted over 18 month duration from 
June 2011 to December 2012.Diagnosis was 
confirmed by real time PCR for BCR-ABL fusion 
transcript. Imatinib was given initially in a dosage of 
400 mg/day and increased to 600 mg/day or to 800 
mg/day (400 mg every 12 hours), if required and 
tolerated[1].Patients with other acute or chronic 
co-morbidities (liver and kidney diseases, other 
malignancies, endocrine disorders besides primary 
hypothyroidism, CML- accelerated phase or blast 
crisis, chronic infections like tuberculosis etc.) were 
excluded. CML – accelerated phase was defined as 
blood or marrow blasts between 10 and 20%, or blood 
or marrow basophils >20%, or platelet count <100 x 
10
9
/L and blast crisis as blood or marrow blasts 
>20%[4].Patients who used drugs with potential 
interference in thyroid function tests in the six months 
prior to the study entry or during follow up were also 
excluded.Haematological remission was defined as 
total leukocyte count<10 x 10
9
/L, platelet count<450 x 
10
9
/L, no immature myeloid cells in the blood, 
disappearance of all signs and symptoms related to 
leukemia (including palpable splenomegaly) lasting 
for at least 4 weeks[1,5].Thyroid function tests - TSH, 
free thyroxin, free tri-iodothyronine and anti - thyroid 
peroxidase antibody,(anti-TPO Ab) for patients with 
elevated TSH,and clinical assessment (for thyroid 
abnormalities)were done at the time of diagnosis 
(baseline).Patients were reassessed for thyroid 
dysfunction after 6 months of imatinib therapy. Ethical 
approval was taken from the institutional board of 
studies. 
Thyroid function tests 
Fasting early morning venous blood sample was taken 
in a plain red capped evacuated blood collection tube 
under all aseptic precautions for TSH, free thyroxin 
(FT4) and free tri-iodothyronine (FT3) estimation by 
chemiluminisence technique on ADVIA Centaur 
system (Siemens) [16].Anti-TPO Abwas estimated 
using chemiluminisence techniqueson Immulite system 
(Siemens) [16].Appropriate external quality controls 
were also run. 
Institutional Reference Intervals used were: 
TSH: euthyroid: 0.35 - 5.50 µIU/mL (mIU/L), 
hyperthyroid: < 0.35 µIU/mL (mIU/L) 
andhypothyroid: > 5.50 µIU/mL (mIU/L).  
FT4: 0.89 - 1.76 ng/dL,  
FT3: 2.3 to 4.2 pg/mL, 
Anti-TPO Ab: < 35 IU/mL 
Subclinical primary hypothyroidism was defined by a 
serum TSHabove the upper reference limit in 
combination with a normalfree thyroxine (T4).Overt 
primary hypothyroidism was defined by a serum 
TSHabove the upper reference limit in combination 
with low free thyroxine (T4) [17,18].Treatment was 
recommended for patients with overt primary 
hypothyroidism and for patients with subclinical 
hypothyroidism with elevated Anti-TPO Ab or TSH > 
10 µIU/mL[17]. 
The data was compiled and subject to statistical 
analysis using SPSS v20. Baseline and post therapy 
values were compared using Wilcoxon sign test. Paired 
proportions were compared by McNemar’s test.  
Observations 
Patient characteristics:In the present study there were 
17 (56.7%) male and 13 (43.3%) female patients 
(1.3:1). Median age at diagnosis was 38.5 years. All the 
patients presented in chronic phase of CML.Median 
haemoglobin levels were 8.5 g/dL and median total 
leucocyte count was 75 X 10
9
/L at presentation. 
Patients had a median of 5.0% blasts in peripheral 
blood at diagnosis. Median platelet count was 300 X 
10
9
/L.Median duration of symptoms in the patients was 
6 weeks. Three out of 30 patients were asymptomatic 
and diagnosed incidentally on routine lab examination.  
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Treatment outcomes:26 patients (87.7%) achieved 
haematological remission at 6 months of imatinib 
therapy while 4 (13.3%) patients were not in remission. 
Imatinib dosage was increased to 600 mg/day in 2 
patients and to800 mg/day in 4 patients.6(20%) 
patients had peripheral edema on legs, 4 (13.3%) had 
periorbital edema, 6 (20%) had fatigue, 5 (16.6%) had 
myalgia, 6 (20%) had cutaneous reactions (rashes) and 
2 (6.6%)patients had complaints of cough as adverse 
effects of imatinib.  
Thyroid function tests (TSH, FT4 AND FT3) at 
baseline: At diagnosis median serum TSH levels were 
2.95 mIU/L, FT4 levels were 1.40 ng/dL and serum 
FT3 levels were 2.60pg/mL (Table 1).Two (6.7%) 
patients had TSH >5.5 mIU/L and normal FT4 and 
FT3 (subclinical hypothyroidism).  Both were not 
receiving any levothyroxine replacement as TPO 
(thyroid peroxidase) antibody levels were within 
reference range and TSH was < 10 mIU/L. 
 
Table 1 Comparisonof 
TSH, FT4 & FT3 levels in CML patients and aftertherapy (M=17, F = 13) 
 
 
 
 
 
 
 
 
Thyroid status after 6 months of imatinib 
therapy:Serum TSH levels increased significantly 
after 6 months of imatinib therapy (3.80±2.00 mIU/L 
vs. 3.14±1.65 mIU/L, p=0.016), though the median 
level (3.75mIU/mL) was in euthyroid range (Table 
1&Fig. 1). 90% patients had euthyroid TSH levels. 3 
patients (10%) had abnormal TSH (>5.5 mIU/L) after 
6 months of imatinib therapy. All three had normal 
FT3 and FT4 (subclinical hypothyroidism). Two of 
these patients had baseline subclinical hypothyroidism 
as well. TSH levels worsened (9.6 mIU/L from 
baseline 7.5 mIU/L  
 
and 7.6 mIU/L from baseline 5.8 mIU/L) form baseline 
in both. In the remaining one patient TSH levels 
worsened from baseline euthyroid levels (baseline 
TSH 3.7 mIU/L, post therapy 6.7 mIU/L). All the three 
patients had TPO levels within reference range and 
TSH < 10 mIU/L.They were not given any treatment 
for thyroid dysfunction.Fatigue, periorbital and 
peripheral edema was present in all three patients. 
There were no other clinical manifestations associated 
with thyroid dysfunction.  
 
 BASELINE 6 MONTHS p value 
TSH 
(mIU/L) 
Mean 3.14 ± 1.65 3.80 ± 2.00 0.016 
Median 2.95 3.75 
Range 0.40 - 7.50 0.80 - 9.60 
FT4 
(ng/dL) 
 
Mean 1.50 ± 0.60 1.42 ± 0.55 0.173 
Median 1.40 1.33 
Range 1.10 - 4.50 0.90 - 4.10 
FT3 
(pg/mL) 
Mean 2.55 ± 0.45 2.71 ± 0.52 0.136 
Median 2.60 2.72 
Range 1.80 - 4.0 1.90 - 3.87 
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Fig. 1 Comparison of S. TSH beforeand after IMATINIB 
therapy in CML patients 
Serum FT4 levels were 1.42±0.55 ng/dL after 6 
months of imatinib therapy as compared to 1.50±0.60 
ng/dL (p = 0.173). Serum FT3 levels were 2.71±0.52 
pg/mL after 6 months of imatinib therapy as compared 
to baseline levels of 2.55±0.45 pg/mL (p = 0.136) 
(Table 1& Fig. 1-3). All levels were in euthyroid 
range. 
 
 
 
 
 
 
 
 
Fig. 2 Comparison of FT4 before and after IMATINIB 
therapy in CML patients 
 
 
 
 
 
 
 
 
 
Fig. 3 Comparison of S. FT3 before and after IMATINIB 
therapy in CML patients 
Discussion 
In the present study male: female ratio was 1.3:1. In 
general, the male predominance has been estimated to 
be 1.3-1.4:1[1,4].Median age at diagnosis was 38.5 
years (15-60 years). Though the incidence of CML has 
been known to increase logarithmically with age, 
Dikshit et al. noted the peak age in younger population 
in hospital based data than the 55-74 years described 
in population based studies[19].Modak et al. also 
described the highest incidence in 36-45 years age 
group[20].We observed a remission rate of 87.7%. The 
hematologic remission rate of patients treated with 
imatinib has been reported to be 95%[1]. 
The prevalence of thyroid abnormalities at baseline 
(6.7%) was similar to the prevalence in general 
population. Patricia et al.has reported a prevalence of 
6.6% for thyroid disorders in general 
population[21].Menon et al. reported a prevalence of 
12.2% for goiter in adult population of an iodine 
sufficient region in India[22].Abraham et al. reported 
a prevalence of 15.8% for thyroid abnormalities 
(mostly subclinical hypothyroidism in women in south 
India[23].Kim et al. and Dora et al. also described 
normal baseline thyroid function in most CML 
patients and that the prevalence of thyroid 
abnormalities was not more than the prevalence in 
general population[12,13].CML itself was not found to 
have any impact on thyroid function by Földes et al., 
who observed that apart from a few cases, there was 
no dysfunction of the pituitary thyroid axis in 
interferon-γ treated CMLpatients in the remission 
phase[24]. 
While TSH levels significantly increased from 
baseline levels, only one patient developed subclinical 
hypothyroidism from previous euthyroid state. TSH 
levels worsened in the two cases of subclinical 
hypothyroidism.90% of patients remained euthyroid 
after 6 months of treatment with imatinib. Imatinib 
therapy did not have any significant impact on thyroid 
status.The findings of the present prospective study 
are consistent with those described by Dora et al.,who 
observed that out of 68 patients of CML on imatinib 
treatment studied,serum TSH was in the normal range 
of 63 out of 68 (92.6%) but slightly elevated in 5 
(7.4%) patients (5.08-12.55 mU/L). All subjects 
displayed levels of T4, FT4, and T3 in the normal 
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range.The serum TSH levels before and after imatinib 
therapy, available only for a subgroup of ten patients, 
were comparable (2.39, 1.82-3.05 mIU/L vs 
2.71,1.71-3.25 mU/L) in their study[13]. 
In the study by Kim et al. only 8 patients were on 
imatinib therapy. While one had hypothyroidism both 
at baseline and after imatinib therapy, one developed 
subclinical hyperthyroidism following therapy[12]. 
Groot et al. reported that there was increased 
symptomatic requirement of levothyroxine and 
elevated TSH whenever imatinib was used in an 
elderlythyroidectomizedpatient for metastatic 
gastrointestinal stromal tumour[14].In another study 
on eleven patients (1 with gastrointestinal stromal 
tumor and 10 with medullary thyroid carcinoma) 
treated with imatinib, Groot et al. observed 
hypothyroid features and increased dosage of 
levothyroxine replacement in all patients who had 
previouslyundergone thyroidectomy, whereas patients 
with the thyroid in situ remained clinically and 
biochemically euthyroid. They reported that TSH 
levels increased to 384±228% of the upper limit in 
patients having thyroidectomy and that imatinib 
associated complications led to the discontinuation of 
therapy in 36% of patients[15].Theincreased demand 
for levothyroxine induced by imatinibin patients under 
levothyroxine replacement mightindicate increased 
peripheral metabolism of thyroid hormones. Induction 
ofhepatic conjugation with glucoronates and sulphates 
has been proposed[12,13].Anotherpotential 
explanation could be increased hormonaldeiodination 
to reverse T3 through enhanced deiodinasetype 3 (D3) 
activity[12,13]. 
Increased peripheral metabolism of thyroid hormones 
may also be responsible for the increase of TSH from 
baseline levels in both euthyroid and subclinical 
hypothyroid subjects in the present study. A normally 
functioning hypothalamic pituitary thyroid axis 
compensates for the possibly altered peripheral thyroid 
hormone metabolism.  
The limitations of present study include absence of a 
healthy control group,small sample sizeand infrequent 
follow up to compare duration of therapy in patients 
with and without thyroid dysfunction. Further studies 
in larger number of patients with frequent and 
prolonged follow up are recommended.  
Conclusions 
Thus we conclude that the thyroid function tests are 
largely unaltered after six months of imatinib therapy 
in CML patients.But the increased TSH suggests 
possible alterations in the peripheral metabolism of 
thyroid hormones. 
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